Zobrazeno 1 - 10
of 1 250
pro vyhledávání: '"Kamyar Kalantar Zadeh"'
Publikováno v:
Turkish Journal of Nephrology, Vol 31, Iss 1, Pp 3-6 (2022)
Externí odkaz:
https://doaj.org/article/d03d976856294244933399fb3e20ce90
Autor:
Carolyn Blair, Joanne Shields, Robert Mullan, William Johnston, Andrew Davenport, Denis Fouque, Kamyar Kalantar-Zadeh, Peter Maxwell, Clare McKeaveney, Helen Noble, Sam Porter, David Seres, Adrian Slee, Ian Swaine, Miles Witham, Joanne Reid
Publikováno v:
International Journal of Nursing Studies Advances, Vol 7, Iss , Pp 100235- (2024)
Background: Chronic kidney disease is common, affecting up to 13 % of the global population, and is predicted to become the fifth leading cause of 'life years lost' by 2040. Individuals with end-stage kidney disease commonly develop complications suc
Externí odkaz:
https://doaj.org/article/a7a7afd96ad849a6aa1e470994087446
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-9 (2024)
Abstract Background Hyperphosphatemia is associated with increased morbidity and mortality in patients with end-stage kidney disease (ESKD). Whereas clinical and observational studies have demonstrated the effectiveness of sucroferric oxyhydroxide (S
Externí odkaz:
https://doaj.org/article/7c199a35c6bc496da5f1a08e75043a98
Autor:
Yoko Narasaki, Csaba P. Kovesdy, Amy S. You, Keiichi Sumida, Yamini Mallisetty, Satya Surbhi, Fridtjof Thomas, Alpesh N. Amin, Elani Streja, Kamyar Kalantar-Zadeh, Connie M. Rhee
Publikováno v:
The Lancet Regional Health. Americas, Vol 36, Iss , Pp 100814- (2024)
Summary: Background: We examined the real-world comparative safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. other newer anti-glycemic medications (dipeptidyl peptidase-4 inhibitors [DPP4i], glucagon-like peptide-1 receptor agonists [
Externí odkaz:
https://doaj.org/article/578ff3bab1c544c8928fcc8422957606
Autor:
Masatsugu Okamura, Masaaki Konishi, Javed Butler, Kamyar Kalantar‐Zadeh, Stephan vonHaehling, Stefan D. Anker
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 14, Iss 4, Pp 1589-1595 (2023)
Abstract Cachexia, in the form of unintentional weight loss >5% in 12 months or less, and secondary sarcopenia in the form of muscle wasting are serious conditions that affect clinical outcomes. A chronic disease state such as chronic kidney disease
Externí odkaz:
https://doaj.org/article/dab06b7d1b6b4cdab717a62169a32df0
Autor:
Ramin Sam, Laura Rankin, Ifeoma Ulasi, Luc Frantzen, Dorothea Nitsch, David Henner, Donald Molony, John Wagner, Jing Chen, Sanjay Kumar Agarwal, Andrew Howard, Ralph Atkinson, Daniel Landry, Stephen O. Pastan, Kamyar Kalantar-Zadeh
Publikováno v:
Kidney Medicine, Vol 6, Iss 3, Pp 100775- (2024)
Vaccinating patients receiving dialysis may prevent morbidity and mortality in this vulnerable population. The National Forum of End-Stage Renal Disease Networks (the Forum) published a revised vaccination toolkit in 2021 to update evidence and recom
Externí odkaz:
https://doaj.org/article/bd10fc7bb7cf484c9a52e1b7abaeddc1
Autor:
Alejandro E. Cañas, Hayden R. Troutt, Luohua Jiang, Sam Tonthat, Omar Darwish, Antoney Ferrey, Shahram Lotfipour, Kamyar Kalantar-Zadeh, Ramy Hanna, Wei Ling Lau
Publikováno v:
BMC Nephrology, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background The KBindER (K+ Binders in Emergency Room and hospitalized patients) clinical trial is the first head-to-head evaluation of oral potassium binders (cation-exchange resins) for acute hyperkalemia therapy. Methods Emergency room and
Externí odkaz:
https://doaj.org/article/39eddc3039f04b63924a910384f854e8
Publikováno v:
ESC Heart Failure, Vol 10, Iss 2, Pp 1294-1304 (2023)
Abstract Aims Iron deficiency is a common finding among patients with heart failure (HF) and is associated with adverse outcomes, including decreased quality of life, increased risk of hospitalization, and decreased survival. Intravenous ferric carbo
Externí odkaz:
https://doaj.org/article/9c503788dd1847b79fbd01eb5d2d8a2e
Publikováno v:
Toxins, Vol 16, Iss 7, p 298 (2024)
Individuals afflicted with advanced kidney dysfunction who require dialysis for medical management exhibit different degrees of native kidney function, called residual kidney function (RKF), ranging from nil to appreciable levels. The primary focus o
Externí odkaz:
https://doaj.org/article/e48b32f9bc234f2ab4f56814b9d5ed1c
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundChronic microinflammation contributes to the progression of chronic kidney disease (CKD). Aspirin (ASA) has been used to treat inflammation for centuries. The effects of long-term low-dose ASA on CKD progression are unclear.MethodsWe examin
Externí odkaz:
https://doaj.org/article/91c15dea3ee04c8eb209f22e30776e95